Kingston - Jamaican sprinters Asafa Powell and Sherone Simpson have settled
a legal case with a nutrition company that sold the supplement Epiphany D1
which contained the banned substance oxilofrine, their management company said
Two years after testing positive for the stimulant, Powell and Simpson have
reached an out-of-court settlement with Dynamic Life Nutrition LLC, according
to a news release.
Details of the settlement were not disclosed. Efforts to contact the
supplement company for independent confirmation were unsuccessful.
The Jamaican pair tested positive for oxilofrine in June 2013 and got
18-month bans which were later reduced on appeal to six months by the Court of
Arbitration for Sport (CAS).
Powell and Simpson, both Olympic relay champions, sued the company for US$8
million after independent laboratory tests revealed that there were
"ingredients in the product (Epiphany D1) that were not listed on the
Despite the settlement, Powell, 32, remains disappointed by what he says is
the damage done to his reputation by the positive test.
"There is no way to really explain the kind of damage a ban has on an
athlete's reputation," said the former world record holder in the 100
metres. "There's no doubt that we're going to continue the fight to repair
it and regain the trust of my fans and fans of the sport."
Simpson, a three-time Olympian, added that while the process had been time
consuming it had not affected them on the track and they were now cautious on
what they took.
"We have a very capable team, and both of us are now extra careful
about our diets and supplement regimen," she said.
The sprinters had testified in an anti-doping disciplinary hearing in
Jamaica and a CAS appeal that they took Epiphany D1 as part of their training
regimen, but later found out that the supplement contained the banned stimulant
Powell and Simpson faced a lengthy anti-doping hearing in Jamaica, forcing
them to miss the 2013 world championships in Moscow, before both were suspended
from athletics for 18 months.
Their sanctions were later cut to six months after CAS found they did not
know the stimulant was present in Epiphany D1.
Epiphany D1 has since been placed on the US Anti-Doping Agency (USADA) high
risk supplement list, warning athletes to avoid the product.